BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 22160081)

  • 1. Relapsed/refractory diffuse large B-cell lymphoma.
    Friedberg JW
    Hematology Am Soc Hematol Educ Program; 2011; 2011():498-505. PubMed ID: 22160081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
    Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
    Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M
    J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse large B cell lymphoma: how can we cure more patients in 2012?
    Moskowitz C
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):41-7. PubMed ID: 22409822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
    Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
    Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
    Hernandez-Ilizaliturri FJ; Czuczman MS
    Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the management of diffuse large B-cell lymphoma.
    Habermann TM
    Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.
    Lukenbill J; Hill B
    Leuk Lymphoma; 2015 Feb; 56(2):293-300. PubMed ID: 24813764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
    Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.